2024
An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis
Ramakrishnan D, Farhat L, Vattimo E, Levine J, Johnson J, Artukoglu B, Landeros-Weisenberger A, Zangen A, Pelissolo A, de B Pereira C, Rück C, Costa D, Mataix-Cols D, Shannahoff-Khalsa D, Tolin D, Zarean E, Meyer E, Hawken E, Storch E, Andersson E, Miguel E, Maina G, Leckman J, Sarris J, March J, Diniz J, Kobak K, Mallet L, Vulink N, Amiaz R, Fernandes R, Shavitt R, Wilhelm S, Golshan S, Tezenas du Montcel S, Erzegovesi S, Baruah U, Greenberg W, Kobayashi Y, Bloch M. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. Journal Of Psychiatric Research 2024, 173: 387-397. PMID: 38598877, DOI: 10.1016/j.jpsychires.2024.03.044.Peer-Reviewed Original ResearchConceptsYale-Brown Obsessive-Compulsive ScaleObsessive-compulsive disorderCGI-IRandomized-controlled trialsAdult obsessive-compulsive disorderClinical Global Impression ImprovementObsessive-Compulsive ScaleTreatment responseIndividual-patient data meta-analysisPosttreatment scoresEvaluation of treatment responseMeta-analysis of randomized-controlled trialsFirst-line therapyCGIIndividual participant dataMeta-analysisNovel treatment modalitiesExpert consensusIndividual participant data meta-analysisSystematic reviewDisordersData meta-analysisPosttreatmentRemission definitionsImpressive improvement
2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2017
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed models
2014
Randomized Sham Controlled Double-blind Trial of Repetitive Transcranial Magnetic Stimulation for Adults With Severe Tourette Syndrome
Landeros-Weisenberger A, Mantovani A, Motlagh MG, de Alvarenga PG, Katsovich L, Leckman JF, Lisanby SH. Randomized Sham Controlled Double-blind Trial of Repetitive Transcranial Magnetic Stimulation for Adults With Severe Tourette Syndrome. Brain Stimulation 2014, 8: 574-581. PMID: 25912296, PMCID: PMC4454615, DOI: 10.1016/j.brs.2014.11.015.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationSham repetitive transcranial magnetic stimulationSupplementary motor areaLow-frequency repetitive transcranial magnetic stimulationFrequency repetitive transcranial magnetic stimulationActive repetitive transcranial magnetic stimulationSevere Tourette syndromeTranscranial magnetic stimulationTourette syndromeTic severityMagnetic stimulationDouble-blind sham-controlled trialEfficacy of rTMSOpen-label active treatmentYGTSS total tic scoreAlternative stimulation protocolsDouble-blind trialOpen-label studySham-controlled trialTotal tic scoreActive rTMS treatmentRandomized ShamRTMS treatmentActive treatmentMotor thresholdMeta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder. Molecular Psychiatry 2014, 19: 1025-1030. PMID: 24912494, PMCID: PMC4169729, DOI: 10.1038/mp.2014.50.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseOCD patientsOdds ratioFurther treatment researchCase-control studyPoor treatment outcomesDifferential treatment responseSymptoms of OCDPrimary outcomeTreatment modalitiesEligible studiesTreatment outcomesPatientsElectronic searchSymptomsTotal participantsBehavioral therapyOCD treatmentDisordersSymptom dimensionsTreatment researchDSM-5Hoarding symptomsTreatment
2013
LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion
2010
Predictors of early adulthood quality of life in children with obsessive–compulsive disorder
Palermo SD, Bloch MH, Craiglow B, Landeros-Weisenberger A, Dombrowski PA, Panza K, Smith ME, Peterson BS, Leckman JF. Predictors of early adulthood quality of life in children with obsessive–compulsive disorder. Social Psychiatry And Psychiatric Epidemiology 2010, 46: 291-297. PMID: 20191262, PMCID: PMC3645906, DOI: 10.1007/s00127-010-0194-2.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderEarly adulthoodOCD symptomsImpaired Functioning ToolMethodsA longitudinal cohort studyLongitudinal cohort studyResultsForty-two percentSeverity of OCDAverage followClinical predictorsCohort studyPoor QoLResidual impairmentMild impairmentQoLSymptomsObjectivesThe goalAnxiety symptomsAdulthoodChildrenQoL.ChildhoodHoarding symptomsImpairmentDisorders
2009
Predictors of Early Adult Outcomes in Pediatric-Onset Obsessive-Compulsive Disorder
Bloch MH, Craiglow BG, Landeros-Weisenberger A, Dombrowski PA, Panza KE, Peterson BS, Leckman JF. Predictors of Early Adult Outcomes in Pediatric-Onset Obsessive-Compulsive Disorder. Pediatrics 2009, 124: 1085-1093. PMID: 19786445, PMCID: PMC3974608, DOI: 10.1542/peds.2009-0015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge of OnsetChildChild, PreschoolCohort StudiesDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceLongitudinal StudiesMaleMonitoring, PhysiologicMultivariate AnalysisObsessive-Compulsive DisorderPredictive Value of TestsProportional Hazards ModelsRisk FactorsSeverity of Illness IndexSex DistributionTic DisordersTime FactorsTourette SyndromeYoung AdultConceptsObsessive-compulsive disorderOCD symptomsBaseline clinical characteristicsPediatric-onset obsessive-compulsive disorderPersistent obsessive-compulsive disorderEarly adult outcomesLong-term outcomesMain outcome measuresLongitudinal cohort studyPercent of subjectsComorbid tic disordersOC symptomsHoarding symptomsAdult outcomesExperience remissionClinical characteristicsClinical predictorsCohort studyOppositional defiant disorderTic symptomsComorbid ticsEligible childrenTic disordersFemale genderOutcome measuresDimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors